Every 424B that Envoy Medical, Inc. (COCH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow COCH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COCH filings page.
Envoy Medical is registering up to 150,803,850 shares of Class A common stock underlying pre-funded, Series A-1, Series A-2 and placement agent warrants, alongside 47,946,150 shares of common stock and 27,053,850 pre-funded warrants sold in a best-efforts public offering at $0.40 per share and accompanying warrants. The deal implies a maximum gross raise of about $30.0 million and estimated net proceeds of roughly $27.8 million before any warrant exercises. There is no minimum offering amount, and H.C. Wainwright is acting as exclusive placement agent.
Common stock outstanding would rise from 28,934,960 to 103,934,960 shares if all pre-funded warrants are exercised and none of the new common or placement agent warrants are exercised. Company insiders are committing about $8.4 million of the raise. Envoy remains a loss-making, emerging growth medical device company, advancing its fully implanted Acclaim cochlear implant through a pivotal trial while facing Nasdaq listing compliance pressures and substantial ongoing capital needs.
Envoy Medical, Inc. is registering up to 150,803,850 shares of Class A common stock issuable from pre-funded, Series A-1, Series A-2 and placement agent warrants, alongside 47,946,150 new shares in a primary offering of stock and warrants at $0.40 per share and accompanying warrants.
The company expects gross proceeds of about $30.0 million and estimated net proceeds of roughly $27.8 million, with no minimum offering requirement in this reasonable best-efforts deal led by H.C. Wainwright. Company insiders plan to buy about 21.0 million shares plus warrants for approximately $8.4 million. Shares outstanding are expected to rise from 28,934,960 to 103,934,960, assuming all pre-funded warrants are exercised and no additional warrants are exercised.
Envoy is a hearing-health company developing the fully implanted Acclaim cochlear implant, now in the final stage of a pivotal U.S. trial, and has never been profitable. It reported net losses of $17.2 million for the nine months ended September 30, 2025 and carries a going-concern warning. The company also faces Nasdaq compliance pressures related to market value and minimum bid price listing standards.